JavaScript Menu Courtesy of Milonic.com
[nucleotide sequence]     [protein sequence]     [ncbi BLAST]     [add construct]     [add ligand annotation]

HR4783B   (GATA4)

2 targets assoicated with this target.
HR4783parentselected
HR4783Asibling(391-442)selected

database refs UniProt: P43694 (GATA4_HUMAN)   |   HUGO: GATA4   |   NCBI gene: 2626   |   refSeq: NP_002043.2
status NMR structure
structures 2M9W (NMR)  
properties length: 60 aa   |   mass: 6.70 kD   |   pI: 10.53   |   ext: 6990   |   organism: Homo sapiens
classes Biomedical: Cancer BioNet T1 (Rutgers), Biomedical: Cancer BioNet T3 (Rutgers), Biomedical: Cancer BioNet, BioMedical, Biomedical: Transcription Factor, PSI-Biology
projects HCPIN     Transcription Factor    
best PDB match calculating ...
informatics Zn binding sites: CH type found (data) CHDE type found (data)
domain signatures3.30.50.10 details   PF00320 details   ZN_FING:GATA-type 2 details   57716 details  
subsequence details   ie 100-200    
BLAST searches

Construct coverage schematic
Display constructs only from this target (HR4783B).
Display constructs associated with this target (HR4783B) and all other associated targets (HR4783, HR4783A).


Domain and UniProt Features
    PFAM PF05349
    SuperFamily 57716
    CATH 3.30.50.10
    Zinc finger - GATA-type 1. {ECO:0000255|PROSITE- domain_number-1
    UniProt ZN_FING:GATA-type 1
    SuperFamily 57716
    CATH 3.30.50.10
    UniProt ZN_FING:GATA-type 2
    PFAM PF00320
    Zinc finger - GATA-type 2. {ECO:0000255|PROSITE- domain_number-1


NESG targets
    HR4783B
    HR4783A

HR4783

       PDB seq homology



Constructs and Most Advanced Status
   
HR4783B-262-321-TEV.*



most recent record
2 years, 18 days ago --     purification [14.8 mg]: HR4783B-262-321-TEV.4-LBd-Ni

2011-06-02    target: HR4783B
2011-06-20    construct: HR4783B-262-321-TEV.3
2011-06-29    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.3-ss
2011-06-20    construct: HR4783B-262-321-TEV.4
2011-06-29    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.4-ss
2011-08-30    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.4-NC5a
2012-03-29    purification [9.9 mg]: HR4783B-262-321-TEV.4-NC5a-Ni
2012-04-03    purification [2.8 mg]: HR4783B-262-321-TEV.4-NC5a-TV
2012-04-10     HR4783B.002 @ Rutgers; 0.04 ml at 1.7 mM
2012-04-13    HSQC [good]: HR4783B.002.600MHz.25C
2012-04-10     HR4783B.003 @ Rutgers; 0.1 ml at 1.7 mM
2011-08-30    expression [ 5, 2, not tested ]: HR4783B-262-321-TEV.4-SeMa
2011-09-19    purification [5.6 mg]: HR4783B-262-321-TEV.4-SeMa-GF
2011-09-27     aggregation screening [#VALUE!,. kD,0.0%]
2011-09-26     HR4783B.001 @ HWI; 0.5 ml at 4.6 mg/mL
2011-08-30    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.4-NC5b
2012-03-29    purification [9.9 mg]: HR4783B-262-321-TEV.4-NC5b-Ni
2012-04-03    purification [2.8 mg]: HR4783B-262-321-TEV.4-NC5b-TV
2011-08-30    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.4-NC5c
2012-11-20    purification [2.6 mg]: HR4783B-262-321-TEV.4-NC5c-Ni
2012-11-20    purification [0.4 mg]: HR4783B-262-321-TEV.4-NC5c-TV
2012-12-05     HR4783B.007 @ Buffalo; 0.4 ml at 0.2 mM
2011-08-30    expression [ 5, 2, not tested ]: HR4783B-262-321-TEV.4-SeMb
2011-09-19    purification [5.6 mg]: HR4783B-262-321-TEV.4-SeMb-GF
2012-05-22    expression [ 4, 4, not tested ]: HR4783B-262-321-TEV.4-NCb
2012-06-26    purification [10.6 mg]: HR4783B-262-321-TEV.4-NCb-Ni
2012-06-26    purification [1.0 mg]: HR4783B-262-321-TEV.4-NCb-TV
2012-05-22    expression [ 4, 4, not tested ]: HR4783B-262-321-TEV.4-NCa
2012-06-26    purification [10.6 mg]: HR4783B-262-321-TEV.4-NCa-Ni
2012-06-26    purification [1.0 mg]: HR4783B-262-321-TEV.4-NCa-TV
2012-06-08    expression [ 5, 4, not tested ]: HR4783B-262-321-TEV.4-NC5d
2012-06-26    purification [10.3 mg]: HR4783B-262-321-TEV.4-NC5d-Ni
2012-06-26    purification [1.1 mg]: HR4783B-262-321-TEV.4-NC5d-TV
2012-08-24    purification [1.0 mg]: HR4783B-262-321-TEV.4-NC5d-GF
2012-07-06     HR4783B.005 @ Buffalo; 0.27 ml at 0.156 mM
2012-06-08    expression [ 5, 4, not tested ]: HR4783B-262-321-TEV.4-NC5e
2012-06-26    purification [10.3 mg]: HR4783B-262-321-TEV.4-NC5e-Ni
2012-06-26    purification [1.1 mg]: HR4783B-262-321-TEV.4-NC5e-TV
2012-08-24    purification [1.0 mg]: HR4783B-262-321-TEV.4-NC5e-GF
2012-07-19    expression [ 4, 1, not tested ]: HR4783B-262-321-TEV.4-NCd
2012-07-26    purification [10.4 mg]: HR4783B-262-321-TEV.4-NCd-Ni
2012-07-26    purification [2.5 mg]: HR4783B-262-321-TEV.4-NCd-TV
2012-08-09    purification [1.7 mg]: HR4783B-262-321-TEV.4-NCd-GF
2012-07-19    expression [ 4, 4, not tested ]: HR4783B-262-321-TEV.4-NCc
2012-07-26    purification [10.4 mg]: HR4783B-262-321-TEV.4-NCc-Ni
2012-07-26    purification [2.5 mg]: HR4783B-262-321-TEV.4-NCc-TV
2012-08-09    purification [1.8 mg]: HR4783B-262-321-TEV.4-NCc-GF
2012-07-06     hr4783b.004 @ Buffalo; 0.3 ml at 1.01 mM
2012-10-18    expression [ 4, 4, not tested ]: HR4783B-262-321-TEV.4-NCe
2012-12-05    purification [3.3 mg]: HR4783B-262-321-TEV.4-NCe-TV
2012-12-20     HR4783B.008 @ Rutgers; 0.25 ml at 0.218 mM
2012-12-05    purification [11.2 mg]: HR4783B-262-321-TEV.4-NCe-Ni
2012-10-18    expression [ 4, 3, not tested ]: HR4783B-262-321-TEV.4-N14a
2012-11-20    purification [0.7 mg]: HR4783B-262-321-TEV.4-N14a-TV
2012-12-05     HR4783B.006 @ Buffalo; 0.4 ml at 0.2 mM
2012-11-20    purification [2.6 mg]: HR4783B-262-321-TEV.4-N14a-Ni
2012-12-03    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.4-NCf
2012-12-03    expression [ 5, 3, not tested ]: HR4783B-262-321-TEV.4-NCg
2013-03-13    expression [ 4, 4, not tested ]: HR4783B-262-321-TEV.4-NCi
2013-03-20    purification [4.5 mg]: HR4783B-262-321-TEV.4-NCi-Ni
2013-03-20    purification [1.6 mg]: HR4783B-262-321-TEV.4-NCi-TV
2013-04-09     HR4783B.009 @ Buffalo; 0.3 ml at 0.378 mM
2013-06-20     NMR structure: 2m9w (PDB)
2013-03-13    expression [ 4, 4, not tested ]: HR4783B-262-321-TEV.4-NCh
2013-03-20    purification [4.7 mg]: HR4783B-262-321-TEV.4-NCh-Ni
2013-03-20    purification [1.3 mg]: HR4783B-262-321-TEV.4-NCh-TV
2013-03-28    expression [ 1, 0, not tested ]: HR4783B-262-321-TEV.4-LBa
2013-05-23    expression [ 4, 2, not tested ]: HR4783B-262-321-TEV.4-LBb
2013-06-04    purification [16.0 mg]: HR4783B-262-321-TEV.4-LBb-Ni
2013-06-12     HR4783B.010 @ CDI Mayaguez, PR; 1.5 ml at 1.4 mg/mL
2013-06-12     HR4783B.011 @ JHU/CDI Baltimore, MD; 1.7 ml at 0.2 mg/mL
2013-06-12     HR4783B.012 @ Rutgers; 2.5 ml at 1.4 mg/mL
2013-06-12     HR4783B.013 @ Rutgers; 12 ml at 0.3 mg/mL
2013-06-06    purification [1.8 mg]: HR4783B-262-321-TEV.4-LBb-GF
2013-06-12     HR4783B.014 @ Rutgers; 9 ml at 0.23 mg/mL
2014-11-12    expression [ 0, 0, not tested ]: HR4783B-262-321-TEV.4-LBc
2014-12-03    expression [ 5, 0, not tested ]: HR4783B-262-321-TEV.4-LBd
2015-01-05    purification [14.8 mg]: HR4783B-262-321-TEV.4-LBd-Ni
2015-01-13     HR4783B.015 @ CDI Mayaguez, PR; 0.25 ml at 3.6 mg/mL
2015-02-13     Entered Ab Pipeline: 2015-02-13; 31 days after shipment
2015-01-13     Passing antibodies: 1
2015-01-13     HR4783B.016 @ JHU/CDI Baltimore, MD; 0.5 ml at 0.2 mg/mL
2015-01-13     HR4783B.017 @ Rutgers; 1 ml at 3.6 mg/mL
2015-01-13     HR4783B.018 @ Rutgers; 3 ml at 1.6 mg/mL
2015-01-13     HR4783B.019 @ Rutgers; 25 ml at 0.2 mg/mL
2015-01-13     HR4783B.020 @ Rutgers; 22 ml at 0.26 mg/mL


Available samples:

LB samples
HR4783B.016 @ JHU/CDI Baltimore, MD HR4783B.010 @ CDI Mayaguez, PR HR4783B.019 @ Rutgers HR4783B.017 @ Rutgers HR4783B.018 @ Rutgers
HR4783B.013 @ Rutgers HR4783B.020 @ Rutgers HR4783B.012 @ Rutgers HR4783B.011 @ JHU/CDI Baltimore, MD HR4783B.015 @ CDI Mayaguez, PR
HR4783B.014 @ Rutgers


SeMet samples
HR4783B.001 @ HWI


NC samples
hr4783b.004 @ Buffalo HR4783B.009 @ Buffalo HR4783B.008 @ Rutgers


NC5 samples
HR4783B.005 @ Buffalo HR4783B.003 @ Rutgers HR4783B.007 @ Buffalo HR4783B.002 @ Rutgers


N14 samples
HR4783B.006 @ Buffalo


E-mail communications associated with this target:

  2012-09-04
  2012-09-05
  2012-12-12
  2013-04-17
  2013-04-17
  2013-06-27
  2013-06-27
  2013-06-28
  2013-06-28
  2013-07-02
  2013-07-02
  2013-08-07
  2013-08-07